Liraglutide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. See also [https://en.wikipedia.org/wiki/Liraglutide]. | Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. See also [https://en.wikipedia.org/wiki/Liraglutide]. | ||
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. See [[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1 and its receptor]]. | Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. See [[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1 and its receptor]] and [[Glucagon]]. | ||
It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. | It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. | ||